Drug Profile
Research programme: restenosis therapeutics - Kereos
Alternative Names: KI-1004Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Kereos
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Coronary artery restenosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Coronary-artery-restenosis in USA
- 31 May 2010 Preclinical trials in Coronary artery restenosis in USA (unspecified route)